Cannabinoids in Neurological & Psychiatric Disorders

This track investigates the emerging evidence for cannabinoids in managing neurological and psychiatric conditions. Presentations will cover epilepsy, multiple sclerosis, Parkinson’s disease, Tourette’s syndrome, PTSD, depression, and anxiety disorders. Emphasis will be placed on neuroprotective effects, synaptic modulation, and mood regulation via the ECS. Clinicians will gain insights into patient selection, risk-benefit analysis, and therapeutic monitoring. Key challenges, such as adverse psychiatric reactions, will also be addressed.

 

    Related Conference of Cannabinoids in Neurological & Psychiatric Disorders

    April 23-24, 2026

    8th World Depression Congress

    Paris, France
    May 14-15, 2026

    9th World Conference on Neuroscience

    Rome, Italy
    June 22-23, 2026

    7th World Congress on Sleep Disorders and Therapeutics

    Amsterdam, Netherlands
    June 22-23, 2026

    18th Global Neurologists Meeting on Neurology and Neurosurgery

    Amsterdam, Netherlands
    June 22-23, 2026

    38th World Conference on Neurology

    Barcelona, Spain
    June 29-30, 2026

    37th Conference on Clinical Neuroscience and Neurogenetics

    Aix-en-Provence, France
    June 29-30, 2026

    39th European Neurology Congress

    London, UK
    July 20-21, 2026

    37th World Congress on Neurology and Neuroscience

    Amsterdam, Netherlands
    July 23-24, 2026

    14th International Conference on Cannabis & Medicinal Research

    Amsterdam, Netherlands
    July 23-24, 2026

    16th Global Alzheimers Summit

    Paris, France
    September 18-19, 2026

    21st Annual Congress on Neuroscience

    Dubai, UAE
    November 16-17, 2026

    8th World Brain Congress

    Tokyo, Japan

    Cannabinoids in Neurological & Psychiatric Disorders Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in